ChondroNest Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 2

ChondroNest General Information

Description

Developer of a patented composition of modified biopolymers designed for cartilage reconstruction. The company's platform vivo reconstruction of the extracellular matrix scaffold, featuring a paste that can be placed and shaped by surgeons to meet individual patient needs, rapidly solidifying in biocompatible conditions, and addressing the minute reconstruction of living tissues, enabling orthopedic surgeons to provide personalized cartilage repair.

Contact Information

Website
www.chondronest.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • Rue des Eterpys 22
  • 1964 Conthey
  • Switzerland
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • Rue des Eterpys 22
  • 1964 Conthey
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ChondroNest Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 02-Jun-2020 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 13-Jan-2016 Cancelled Pre-Clinical Trials
2. Angel (individual) 13-Jan-2016 $443K $443K Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Nov-2015 Completed Pre-Clinical Trials
To view ChondroNest’s complete valuation and funding history, request access »

ChondroNest Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • Pending

  • Expiring in next 12 mo

ChondroNest Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200017518-A1 Bis-cyclic carbonate molecule with bis(1,3)-dioxin-dione structure Inactive 16-Dec-2016
EP-3555058-A2 Bis-cyclic carbonate molecule with bis(1,3)-dioxin-dione structure Inactive 16-Dec-2016
ES-2729301-T3 Composition containing glycosaminoglycans and proteins Active 18-Sep-2014
US-10478523-B2 Composition containing glycosaminoglycans and proteins Inactive 18-Sep-2014
US-20170296698-A1 Composition containing glycosaminoglycans and proteins Active 18-Sep-2014 A61L27/26
To view ChondroNest’s complete patent history, request access »

ChondroNest Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
MassChallenge Accelerator/Incubator
Fondation The Ark Accelerator/Incubator
To view ChondroNest’s complete investors history, request access »

Ready to get started?

Request a free trial

ChondroNest FAQs

  • When was ChondroNest founded?

    ChondroNest was founded in 2015.

  • Where is ChondroNest headquartered?

    ChondroNest is headquartered in Conthey, Switzerland.

  • What industry is ChondroNest in?

    ChondroNest’s primary industry is Biotechnology.

  • Is ChondroNest a private or public company?

    ChondroNest is a Private company.

  • What is ChondroNest’s current revenue?

    The current revenue for ChondroNest is .

  • How much funding has ChondroNest raised over time?

    ChondroNest has raised $443K.

  • Who are ChondroNest’s investors?

    MassChallenge and Fondation The Ark have invested in ChondroNest.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »